Introduction. Hypertension is one of the most common risk factors of cardiovascular disease, which remains the major cause of death in Poland. Number of patients with controlled hypertension remains low. The aim of the study was to evaluate strategies of hypotensive pharmacotherapy, to determine prevalence of poorly controlled hypertension and of cardiovascular risk factors and comorbidities in these patients.
Introduction
Cardiovascular diseases, including myocardial infarction, heart failure or stroke, are major causes of death in Poland. Idiopathic arterial hypertension is a strong risk factor for developing cardiovascular disease. Epidemiological studies show that arterial hypertension may be found in 25-30% adults in Poland, and prevalence increases with age, reaching 50% in general population of over 40 years of age [1, 2] . Despite certain improvement, percentage of patients with adequately controlled hypertension remains low and amounts only 26%, according to the NATPOL 2011 study [3] .
Most patients with hypertension have also other risk factors for developing cardiovascular disease, complications or comorbidities.
According to guidelines issued by Polish and international cardiologic and hypertension societies, global cardiovascular risk should be assessed in every person with arterial hypertension, with evaluation of other risk factors, subclinical organ damage, and comorbidities [4, 5] . Patient's individual risk profile is crucial for selection of optimal therapeutic strategies, involving initiation of pharmacotherapy, motivation for lifestyle change, and adequate drug choice.
Aims of the study
Main goal 1. Evaluation of antihypertensive pharmacotherapy, including analysis of drug classes fixed-dose combinations, dosage and therapy modifications.
Secondary goals
2. Estimation of prevalence of poorly controlled disease in patients with diagnosed arterial hypertension followed in outpatient care setting. 3 . Evaluation of prevalence of main risk factors for cardiovascular diseases, subclinical signs of organ damage, and comorbidities in patients with poorly controlled arterial hypertension.
Material and methods
The study had non-interventional observational design, and involved physicians from primary and secondary outpatient healthcare facilities throughout Poland, who diagnose and treat arterial hypertension.
No additional diagnostic tests or monitoring-intended measures beyond routine work-up for arterial hypertension were undertaken during data collection.
The study was organized and sponsored by Servier Poland. The study had two stages, both completed during a single patient appointment: -screening -collection of baseline medical data (age, sex, systolic and diastolic blood pressure values [SBP/
/DBP], information on applied hypotensive therapy) in 50 consecutive patients with arterial hypertension attending a single physician; -collection of additional medical data, using the provided form, in 10 patients selected by each physician from his screening group. These subjects fulfilled the following criteria:
• more than 18 years of age,
• poorly controlled arterial hypertension, defined as SBP over 140 mm Hg and/or DBP over 90 mm Hg measured in office, on the day of appointment. Additional collected data concerned: • physician specialty, affiliation, date of appointment; • patient data: age, sex, body weight, body height, waist circumference, heart rate, SBP/DBP measured in office, SBP/DBP measured at home, main risk factors including tobacco smoking, dyslipidemia, family history of cardiovascular disease at an early age (males < 55 years, females < 65 years), abdominal obesity (M ≥ 94 cm, F ≥ 80 cm), glycemic aberrations, signs of organ damage and comorbidities. Among the latter, the following entities and conditions were recorded: diabetes, kidney dysfunction (defined as microalbuminuria or increased plasma creatinine), chronic kidney disease (defined as proteinuria, diabetic nephropathy or renal failure), ischaemic heart disease, myocardial infarction, heart failure, cerebrovascular disease (stroke or transient ischaemic attack [TIA]), and peripheral artery disease; • information on hypotensive therapy: duration of treatment, time from last modification of therapy, administered drugs and their dosage. The data was collected in Microsoft Access file, and submitted to statistical analysis, which was performed using the SAS software build 9.1.
Characteristics of the study group was provided in a standard way, with quantitative variables of nearly normal distribution presented as mean values with standard deviation; for variables of strongly asymmetric distribution, median value and interquartile range were presented. Qualitative variables were presented as percentage in respective categories.
Results
Data were collected between February and July 2013 by 857 physicians having the following specialist competence: family medicine 31.2%, internal medicine 60.3%, cardiology 17.5%, and other specialty 10.9%.
Most data were collected at primary level healthcare institutions (64.5%), followed by specialist outpatient institutions (23.3%), private practice (7.4%), and other institutions (3.3%). Half of all patients were pharmacologically treated for hypertension for at least 5 years, and 21.7% for more than 10 years. The most commonly used pharmacological agent classes included angiotensin converting enzyme inhibitors (59.7%), beta-blockers (45%), and diuretics (38.7%). Calcium antagonists were administered in 33.5% patients, and angiotensin receptor blockers in 13.5%.
Seventy-three percent of all patients were treated with more than one hypotensive agent, mostly using several individual drugs. Fixed-dose combinations (combination of two or three different agents in a single dosage form) were used in only 10.6% patients.
Data concerning time from last modification of pharmacotherapy are presented in figure 4. Hypotensive therapy was not modified for at least half a year in 61.4% patients.
Discussion
POSTER study (POStępowanie TERapeutyczne u pacjentów z niekontrolowanym nadciśnieniem tętniczym w lecznictwie otwartym w Polsce; therapeutic strategies in poorly controlled hypertension in outpatient setting in Poland) was carried out in 2013, and included more than 40,000 patients with arterial hypertension in the screening stage.
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Most patients (almost two thirds of the screened cohort) were taken care of by physicians in primary healthcare setting, whereas the others were treated in specialist institutions. Majority of patients (54%) had poorly controlled arterial hypertension, i.e. systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg. As many as 14.5% of patients were not administered any hypotensive pharmacologic agents. A similar study performed in 2002 (NATPOL) identified 18% of patients with diagnosed but pharmacologically untreated arterial hypertension, and 82% of all then analyzed patients were not optimally treated. Unpublished data from NATPOL 2011 study suggested that blood pressure control improved (as compared to NATPOL 2002 study), with 13% of patients having diagnosed but untreated hypertension, and 64% being suboptimally treated [3] . POLSENIOR study, which included approximately 5,000 persons of more than 64 years of age, gave similar results, with treated but poorly controlled arterial hypertension in 65% of subjects [6] . POSTER study reveals improved blood pressure control, which is an optimistic finding, and hopefully represents a new positive trend. Similar observational studies from other countries showed largely varying results as to amounts of patients with non-optimal blood pressure control under treatment, with 66% such persons identified in Portugal [7] but only 16% in USA or Canada [8] .
Second stage of the presented study involved 8,766 persons selected due to poorly controlled hypertension despite ongoing treatment, and these subjects were further analyzed in respect to comorbidities, cardiovascular risk factors and details of hypotensive therapy. Mean systolic blood pressure in this population was 158 mm Hg, which is almost 20 mm Hg higher than the desired value. Mean diastolic pressure was 94 mm Hg, and mean body mass index (BMI) value was 29.4 kg/m 2 , which is almost exactly at the threshold for obesity diagnosis. More than half of all patients (56%) declared regular blood pressure measuring at home. Mean value of blood pressure recorded at home by patients themselves was 150/90 mm Hg, which confirms non-optimal control of hypertension, since target value for at home measurement is < 135/85 mm Hg. Main risk factors for cardiovascular disease identified in the study population included dyslipidemia (78%) and abdominal obesity (68%), with almost 25% patients admitting smoking habit. As to comorbidities, 33.4% patients had coronary heart disease, 12.3% had previously had a myocardial infarct, 31% had Figure 1 . Distribution of major cardiovascular risk factors and comorbidities in patients with poorly controlled arterial hypertension; IHD -ischaemic heart disease; PAD -peripheral artery disease; CHF -chronic heart failure; TIA -transient ischaemic attack diabetes, and 11.4% suffered from heart failure. When comparing the presented data to results of the NATPOL 2011 study, which included a representative sample of Polish adult general population, it should be noted that prevalence of potentially modifiable cardiovascular disease risk factors in the presented POSTER study was markedly higher than in general population, where hypercholesterolemia was found in 61% persons, obesity in 22% persons, diabetes in 5% subjects, and 27% adults admitted smoking tobacco. Particularly worrying is the fact that prevalence of diabetes is six times higher and smoking habit much more common in patients who already have increased cardiovascular risk, and are being controlled by a physician when compared to respective indices in general population. Another study, POLSENIOR, found prevalence of diabetes to be 22% in elderly population. Different prevalence figures cannot be explained just by older patient age in POSTER study (mean age 61 years) than in NATPOL study. Analysis concerning pharmacotherapy revealed that almost three forms of all patients are administered more than one hypotensive drug. The most commonly used agents include angiotensin converting enzyme inhibitors (60%), beta-blockers (45%), diuretics (39%), and calcium channel antagonists (34%). Fixed-dose combinations were administered in only 10% of patients. In the diuretic-treated group, the most often chosen agent was indapamide (64% of all patients receiving diuretics), which is believed to be metabolically neutral. Therapy was not modified for at least half a year in more than 60% of patients, despite proven poor control of their hypertension. The latter finding is consistent with other observational studies, confirming existence of the so-called therapeutic inertia, which is defined as failure of health-care provider to reach therapeutic goals by not increasing dosage of the drug the patient is already taking and/or not adding another agent [9] . Study results support the already published findings which point to the necessity of using more than one hypotensive agent for proper blood pressure control [10] . Pharmacologic agents used in the current study are compatible with recommendations of Polish and international hypertension societies. In many studies, fixed-dose combinations proved Danuta Czarnecka et al., POSTER study more efficient, producing a more prominent hypotensive effect, with better tolerance, and a simpler administration regimen, which in turn contributed to better patient compliance. These drugs are, however, still not commonly used in Poland [11] . Usage of hypotensive fixed-dose combinations is currently recommended not only to simplify multidrug therapy but also as single agent therapy, in patients with grade 2 arterial hypertension and/or cardiovascular and renal complications of hypertension [5] .
Unwillingness to modify pharmacotherapy despite obvious inefficacy of the current treatment is another worrying conclusion. This might be due to lacking knowledge of desired blood pressure values, alternatively because of fear of too strong blood pressure reduction or of adverse effects of hypotensive agents.
Large number of patients recruited mainly in primary healthcare institutions is the strength of POSTER study, as other reports confirmed that just primary healthcare services deal with most hypertensive patients. Furthermore, the study is the first ever attempt to describe patients with poorly controlled arterial hypertension in Poland. Limitation of the study is lack of comparison of patients with controlled hypertension and subjects with poorly controlled disease, and not identifying risk factors of poor blood pressure control. POSTER study is an important step to describe and understand the profile of Polish patients with arterial hypertension, as it includes patients that most physicians meet in daily practice, i.e. patients with poorly controlled hypertension.
Conclusions
1. More than half (54.3%) of all patients with arterial hypertension treated in outpatient setting did not achieve target blood pressure values. 2. The most common cardiovascular risk factors and comorbidities in patients with poorly controlled arterial hypertension included dyslipidemia, abdominal obesity, ischaemic heart disease, and diabetes. 3. Almost three thirds of all patients with poorly controlled arterial hypertension were administered more than one hypotensive agent, most often angiotensin converting enzyme inhibitor, beta-blocker or diuretic. Fixed-dose combinations were used in approximately 10% of patients. 4. Hypotensive pharmacotherapy was not modified for more than half a year in over 60% of patients, despite signs of poor blood pressure control.
Streszczenie
Wstęp. Nadciśnienie tętnicze jest jednym z najczęstszych czynników ryzyka chorób układu sercowo-naczyniowego stanowiących główną przyczynę zgonów w Polsce. Liczba pacjentów z kontrolowanym nadciśnieniem tętniczym wciąż pozostaje mała. Celem pracy była ocena sposobów farmakoterapii nadciśnienia tętniczego, określenie częstości występowania niekontrolowanego nadciśnienia tętniczego oraz częstości występowania czynników ryzyka chorób chorób układu sercowo-naczyniowego i chorób współistniejących w tej grupie pacjentów.
Materiał i metody. Przeprowadzono nieinterwencyjne badanie obserwacyjne wśród pacjentów ambulatoryjnej opieki medycznej. Badanie składało się z dwóch części: 1) badań przesiewowych, tj. zebrania podstawowych danych medycznych od 50 pacjentów z nadciśnieniem tętniczym; 2) zebrania dodatkowych danych medycznych od 10 chorych z niekontrolowanym nadciśnieniem tętniczym.
Wyniki. W badaniu na etapie badań przesiewowych uczestniczyło 42 338 pacjentów. U 54,3% badanych stwierdzono brak kontroli nadciśnienia tętniczego. W tej grupie do najczęściej stwierdzanych czynników ryzyka chorób układu sercowo--naczyniowych należały zaburzenia lipidowe (77,8%) oraz otyłość brzuszna (68,3%). Ponad 25% badanych paliło tytoń. Najczęściej stwierdzanymi chorobami współistniejącymi były choroba niedokrwienna serca oraz cukrzyca (odpowiednio 33,4% i 31%). W ramach leczenia hipotensyjnego 73% pacjentów przyjmowało więcej niż jeden lek przeciwnadciśnie-niowy (najczęściej inhibitor konwertazy angiotensyny 59,7%, beta-adrenolityk 45% i diuretyk 38,7%), a 10,6% badanych przyjmowało lek złożony. Terapia hipotensyjna nie była modyfikowana od ponad roku u 38% pacjentów.
Wnioski. Spośród pacjentów z nadciśnieniem tętniczym pozostających pod opieką ambulatoryjną wciąż ponad połowa nie osiąga docelowych wartości ciśnienia. W tej grupie najczęstszymi czynnikami ryzyka i chorobami współistniejącymi są: zaburzenia lipidowe, otyłość brzuszna, choroba niedokrwienna serca i cukrzyca. Prawie 3/4 pacjentów przyjmuje więcej niż jeden lek hipotensyjny -najczęściej inhibitor konwertazy angiotensyny, beta-adrenenolityk i diuretyk. U ponad 60% chorych od ponad pół roku nie modyfikowano leczenia przeciwnadciśnieniowego.
Słowa kluczowe: niekontrolowane nadciśnienie tętnicze, czynniki ryzyka, choroby współistniejące, terapia hipotensyjna (Folia Cardiologica 2015; 10, 4: 242-248) mywało leki hipotensyjne. U 1/4 chorych stosowano monoterapię, natomiast u pozostałej części chorych stosowano więcej leków, w tym u blisko 30% -3 lub więcej leków hipotensyjnych. Podobny odsetkowy podział dotyczący liczby przepisywanych leków obserwuje się w innych badaniach, choć uczestniczyli w nich chorzy z zadowalającą kontrolą ciśnienia tętniczego [3] .
Bardzo interesujące jest zestawienie grup leków stosowanych przez lekarzy. Osobiście nie dziwi mnie częste podawanie inhibitorów konwertazy angiotensyny, w tym perindoprilu i ramiprilu. Skuteczność obu tych leków jest dobrze udokumentowana, między innymi w badaniach u chorych na cukrzycę i z chorobą wieńcową, a pacjentów z tymi obcią-żeniami było wielu w badanej grupie. U znacznego odsetka stosowano diuretyki, w tym głównie indapamid, co świadczy o znajomości badań i zalet tego leku w terapii nadciśnienia. Zastanawia, że tak liczna grupa chorych otrzymywała beta-adrenolityki. Liczne badania, na przykład LIFE czy ASCOT, wskazują, że leki te przynoszą pacjentom mniejsze korzyści niż pozostałe grupy leków hipotensyjnych [4, 5] . Być może, wysoki odsetkowy udział beta-adrenolityków w leczeniu wynika ze współistnienia u chorych choroby wieńcowej i niewydolności serca. W ostatnich latach wiele mówi się o terapii lekami złożonymi, zawierającymi dwa lub trzy preparaty w jednej tabletce. Ich rolę w leczeniu nadciśnienia, zwłaszcza powikłanego i współistniejącego z innymi chorobami, podkreśla się w europejskich i polskich zaleceniach. Wiele wskazuje na to, że lekami złożonymi w mniejszych dawkach można również, w miejsce klasycznej monoterapii, inicjować leczenie nadciśnienia tętniczego. W najnowszych wytycznych Polskiego Towarzystwa Nadciśnienia Tętniczego zaleca się nawet rozpoczynanie leczenia od leków złożonych u chorych z nadciśnieniem 2. stopnia [6] . Podczas terapii lekami złożonymi, w porównaniu z substancjami stosowanymi oddzielnie, obserwuje się mniejszą liczbę działań niepożądanych, większą tolerancję i poprawę współpracy z chorymi, a co za tym idzie -lepszą kontrolę ciśnienia tętniczego. Nierzadko leki te są również tańsze od swoich odpowiedników podawanych osobno. Mimo dostępności różnorodnych preparatów i w wielu dawkach w badanej populacji tylko 10% chorych otrzymywało leki złożone. W części krajów europejskich leki konfekcjonowane w jednej tabletce są stosowane 5-krotnie częściej [7] . Przekłada się to na wyższy odsetek chorych z dobrą kontrolą ciśnienia tętniczego. Na koniec trzeba zwrócić uwagę na fakt, że w badaniu tym u ponad 60% chorych ze źle kontrolowanym nadciśnie-niem tętniczym stwierdzono brak modyfikacji terapii hipotensyjnej przez pół roku! Inercja lekarska jest zjawiskiem powszechnym na całym świecie. Najczęściej wynika z obaw, że modyfikacja leczenia przyczyni się do nadmiernego spadku ciśnienia i nasilenia objawów niepożądanych. Należy jednak pamiętać, że opóźnianie czasu do osiągnięcia docelowych wartości ciśnienia może już w okresie kilku miesięcy znacząco zwiększyć ryzyko wystąpienia poważnych powikłań sercowo-naczyniowych.
Badanie POSTER dowodzi, jak wiele jeszcze trzeba zmienić w opiece nad chorymi z nadciśnieniem tętniczym.
Piśmiennictwo

